STEPHAN MOSS: Open Payments
NPI 1063906857 · BRIGHAM CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$861 in 53 payments from 10 companies in 2025. Trend: 2023 $1,121 · 2024 $964 · 2025 $861
Food & beverage: $861
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $285 |
| Amgen Inc. | 18 | $221 |
| AstraZeneca Pharmaceuticals LP | 2 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Astellas Pharma US Inc | 1 | $31 |
| Abbott Laboratories | 1 | $23 |
| PFIZER INC. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Organon LLC | 1 | $12 |
Products named: VRAYLAR, QULIPTA, OTEZLA, AIRSUPRA, CAPLYTA, EVENITY, FARXIGA, TAVNEOS.
Industry payments across UT — which companies pay providers there.
